Navigation Links
Cotara in Medical News

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

... At the same time, we advanced our bavituximab and cotara clinical trials in FY 2009 while keeping R&D c...ology platform." Mr. King continued, "Our cotara clinical program continues to advance with patient...icine 2009 Annual Meeting, further confirming that cotara specifically localizes to brain tumors at high con...

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program

...Phase I and Phase II Clinical Trials Have Received cotara to Date, with a Good Safety Profile and Longer-Ter...patient enrollment in the final cohort of a second cotara GBM trial, a dose confirmation and dosimetry study... than 65 patients with recurrent GBM have received cotara in the current and previous clinical studies. Loc...

Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials

...fficacy trial. In patients treated in the studies, cotara appears to be safe and well tolerated, with no dos..."We are encouraged by early results from these two cotara clinical studies and look forward to presenting da...s in this trial receive an initial imaging dose of cotara before receiving the therapeutic dose. The study's...

Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial

...dly form of brain cancer. In pilot studies cotara has shown encouraging results, demonstrating a 58%...ma trials would provide a foundation for advancing cotara into Phase III trials. "Cotara has demonst...ry and dosing data being collected in ongoing U.S. cotara trials, will help us determine the optimal design ...
Cotara in Medical Technology

Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

...s with minimal radiation exposure to other organs. cotara is a targeted monoclonal antibody linked to a radi...a multiforme (GBM), a deadly form of brain cancer. cotara specifically targets cells at the center of brain ...study, confirming other clinical data showing that cotara appears to have a good safety profile. The...

Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India

...aging signs of anti-tumor activity seen in earlier cotara brain cancer studies," said Steven W. King, presid...ective is to confirm the maximum tolerated dose of cotara in these GBM patients. Secondary objectives includ...ts in the trial are receiving a single infusion of cotara by convection-enhanced delivery (CED), an NIH-deve...
Cotara in Biological Technology

Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine

...se, and it can produce large quantities of labeled drug product rapidly, reliably and cost-effectively. We have been using the new process to produce cotara for our ongoing brain cancer trials and can report that it works as well in clinical practice as it does in the lab. We believe it is significant tha...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... with minimal radiation exposure to other organs. cotara is a targeted monoclonal antibody linked to a radi...rst two cohorts of the study, the concentration of cotara in brain tumors was on average more than 300-fold ...al time of six months for recurrent GBM patients. cotara is currently being tested in this Phase I dose res...

Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009

...rior bavituximab cancer study and from our ongoing cotara study in glioblastoma (GBM) patients at the presti...(R) Brain Cancer Program: Peregrine advanced the cotara brain cancer program during the quarter. -- Presented data from the cotara dosing and dosimetry study at the ASCO 2008 Annual...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008

...tudy in HCV patients co-infected with HIV, and two cotara studies for the treatment of glioblastoma multifor...we strengthened the foundation for progress in the cotara clinical program by initiating additional sites in two ongoing trials of cotara in patients with GBM. Data was presented at the 20...

Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study

... in brain tumors, leaving healthy tissue in the body largely unaffected. The release also reported that all of the GBM patients treated to date in the cotara Phase II safety and efficacy trial have survived past the expected median survival time for relapsed GBM patients, an early but encouraging result. Th...

Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008

... distinguished brain cancer center and experienced cotara clinical study site -- the Barrow Neurological Ins...tiative to raise awareness for the bavituximab and cotara programs in the scientific and medical communities...ek of an abstract discussing patient data from the cotara dosimetry trial for presentation at the 2008 ASCO ...

Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008

...nd demonstrated encouraging signs of anti-viral activity. Cotara(R) Brain Cancer Clinical Program To help accelerate the ongoing Phase II trial of cotara in patients with glioblastoma multiforme, one of the most deadly forms of brain cancer, Peregrine recently added two new sites to the study, for a tot...
Other Tags
(Date:12/22/2014)... Fad diets have been around forever ... most fad diets have hung around so long is that ... is that, as the body becomes accustomed to new eating ... to reset the metabolism to return the body to fast ... all-inclusive diet plans that are medically supervised throughout. ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting company, ... ad hoc report writing service to meet the high ... for an annual subscription and get a fixed number ... discounted hourly rate. , Customers can choose from ... rate. Subscription hours are contracted in 25 hour increments. ...
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... SUNDAY, Dec. 21, 2014 (HealthDay News) -- A new ... cow disease" in deer might also protect livestock and ... The vaccine appears to help prevent deer from becoming ... wasting disease, according to the report in the Dec. ... Chronic wasting disease is caused by mysterious infectious particles ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
(Date:12/19/2014)... 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in July 2012, Apple introduced the fingerprint reading ... the only device of Apple incorporating such a ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014 /PRNewswire/ ... the publication of a study that pinpoints fine-scale differences ... the United States . Since immigrants ... the United States has served as ... study illuminates how American history and the ongoing mixing ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
Other Contents